HUP9903166A2 - Gyógyászati készítmények arterioszklerózis megelőzésére vagy kezelésére - Google Patents

Gyógyászati készítmények arterioszklerózis megelőzésére vagy kezelésére

Info

Publication number
HUP9903166A2
HUP9903166A2 HU9903166A HUP9903166A HUP9903166A2 HU P9903166 A2 HUP9903166 A2 HU P9903166A2 HU 9903166 A HU9903166 A HU 9903166A HU P9903166 A HUP9903166 A HU P9903166A HU P9903166 A2 HUP9903166 A2 HU P9903166A2
Authority
HU
Hungary
Prior art keywords
derivatives
angiotensin
indione
receptor antagonists
insulin resistance
Prior art date
Application number
HU9903166A
Other languages
English (en)
Inventor
Toshihiko Fujiwara
Naoyuki Maeda
Toshio Sada
Yoshio Tsujita
Original Assignee
Sankyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co., Ltd. filed Critical Sankyo Co., Ltd.
Publication of HUP9903166A2 publication Critical patent/HUP9903166A2/hu
Publication of HUP9903166A3 publication Critical patent/HUP9903166A3/hu
Publication of HU225415B1 publication Critical patent/HU225415B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány őlyan gyógyászati készítményekre vőnatkőzik, amelyekhatóanyagként egy vagy több, angiőtenzin II receptőr antagőnisták ésangiőtenzinkőnvertáló enzim inhibitőrők közül megválasztőtthatóanyagőt és egy vagy több inzűlin rezisztenciafőkőzó ágensttartalmaznak. A találmány szerinti készítmények az anteriőszklerózismegelőzésére vagy kezelésére alkalmasak. A találmány tárgya tővábbákísérleti kit amely legalább két tárőlásra alkalmas, egymástólteljesen vagy részben különböző eszközből áll, és legalább egy ilyeneszköz legalább egy inzűlinrezisztencia-főkőzó ágenst és legalább egyilyen eszköz legalább egy, angiőtenzin II receptőr antagőnisták ésangiőtenzinkőnvertáló enzim inhibitőrők közül megválasztőtthatóanyagőt tartalmaz. A fenti angiőtenzin II receptőr antagőnstákpéldáűl bifeniltetrazőlszármazékők és bifenilkarbőnsavszármazékőkközül vannak megválasztva, az angiőtenzin kőnvertáló enzim inhibitőrőkpedig tetrahidrődiazepin-származékők prőlinszármazékők,piridazinődiazepinszármazékők glicinszármazékők,imidazőlidinszármazékők és izőkinőlinszármazékők közül vannakmegválasztvá, az inzűlinrezisztencia-főkőzó ágensek atiazőlidindiőnszármazékők, őxazőlidindiőnszármazékők és azőxadiazőlidindiőnszármazékők közül vannak megválasztva. ŕ
HU9903166A 1996-07-15 1997-07-11 Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma HU225415B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15
PCT/JP1997/002407 WO1998002183A1 (en) 1996-07-15 1997-07-11 Medicinal compositions

Publications (3)

Publication Number Publication Date
HUP9903166A2 true HUP9903166A2 (hu) 2000-09-28
HUP9903166A3 HUP9903166A3 (en) 2003-09-29
HU225415B1 HU225415B1 (en) 2006-11-28

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0600501A HU227399B1 (en) 1996-07-15 1997-07-11 Use of cs-866 for producing pharmaceutical composition for the treatment of arteriosclerosis
HU9903166A HU225415B1 (en) 1996-07-15 1997-07-11 Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0600501A HU227399B1 (en) 1996-07-15 1997-07-11 Use of cs-866 for producing pharmaceutical composition for the treatment of arteriosclerosis

Country Status (19)

Country Link
US (1) US6610682B2 (hu)
EP (2) EP1175902B1 (hu)
KR (1) KR100540618B1 (hu)
CN (2) CN1221259C (hu)
AT (2) ATE306921T1 (hu)
AU (1) AU714618B2 (hu)
CA (1) CA2261040C (hu)
CZ (2) CZ299162B6 (hu)
DE (2) DE69731840T2 (hu)
DK (2) DK1175902T3 (hu)
ES (2) ES2250283T3 (hu)
HK (1) HK1020260A1 (hu)
HU (2) HU227399B1 (hu)
IL (2) IL128059A (hu)
NO (2) NO322314B1 (hu)
NZ (1) NZ333723A (hu)
PT (1) PT930076E (hu)
RU (2) RU2220723C2 (hu)
WO (1) WO1998002183A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
MXPA02010090A (es) * 2000-04-12 2003-02-12 Novartis Ag Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EA009983B1 (ru) * 2003-01-31 2008-04-28 Дайити Санкио Компани, Лимитед Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
RU2011124948A (ru) * 2008-11-19 2012-12-27 Мериал Лимитед Композиции, включающие 1-арилпиразол сам по себе или в комбинации с формамидином, для лечения паразитарных инфекций
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
NO303782B1 (no) * 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1215338A (zh) 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物

Also Published As

Publication number Publication date
HU227399B1 (en) 2011-05-30
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
PT930076E (pt) 2005-01-31
EP1175902A1 (en) 2002-01-30
NO990166D0 (no) 1999-01-14
RU2220723C2 (ru) 2004-01-10
EP0930076A4 (en) 2001-10-04
KR20000023757A (ko) 2000-04-25
ES2250283T3 (es) 2006-04-16
ES2232873T3 (es) 2005-06-01
NO20056021L (no) 1999-03-15
EP0930076B1 (en) 2004-12-01
CN1230122A (zh) 1999-09-29
HUP9903166A3 (en) 2003-09-29
CN1476833A (zh) 2004-02-25
US6610682B2 (en) 2003-08-26
HU225415B1 (en) 2006-11-28
AU3459597A (en) 1998-02-09
ATE306921T1 (de) 2005-11-15
HK1020260A1 (en) 2000-04-07
US20020013308A1 (en) 2002-01-31
EP1175902B1 (en) 2005-10-19
ATE283704T1 (de) 2004-12-15
IL145758A (en) 2006-06-11
EP0930076A1 (en) 1999-07-21
IL128059A (en) 2003-12-10
HUP0600501A3 (en) 2008-10-28
DE69734405T2 (de) 2006-08-03
CA2261040C (en) 2009-01-20
IL128059A0 (en) 1999-11-30
HU0600501D0 (en) 2006-08-28
CN1221259C (zh) 2005-10-05
DE69731840T2 (de) 2005-08-04
DK1175902T3 (da) 2005-12-19
KR100540618B1 (ko) 2006-01-12
DE69734405D1 (de) 2006-03-02
NO322314B1 (no) 2006-09-11
RU2183128C2 (ru) 2002-06-10
CZ300089B6 (cs) 2009-01-28
WO1998002183A1 (en) 1998-01-22
NZ333723A (en) 2000-09-29
DE69731840D1 (de) 2005-01-05
CN1155409C (zh) 2004-06-30
NO334217B1 (no) 2014-01-13
NO990166L (no) 1999-03-15
AU714618B2 (en) 2000-01-06
CA2261040A1 (en) 1998-01-22
DK0930076T3 (da) 2005-01-31

Similar Documents

Publication Publication Date Title
HUP9903166A2 (hu) Gyógyászati készítmények arterioszklerózis megelőzésére vagy kezelésére
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
HUP9903918A2 (hu) Fibrózis gátlására alkalmas szomatosztatin agonistát tartalmazó gyógyszerkészítmények
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
HUP0000492A3 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
CA2261848A1 (en) Cell adhesion inhibitors
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
BG106030A (en) Pharmaceutical composition
IL130349A0 (en) Substituted nitrogen containing heterocycles as inhibitors of P38 protein pinase and pharmaceutical compositions containing the same
PT951473E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
DE69729183T2 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
TR199901274T2 (xx) Farnezil protein transferaz inhibit�rleri olarak yararl� yeni trisiklik piperidinil bile�ikleri
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
HUP0200519A2 (hu) Angiotenzin átalakító enzim inhibitort és epoxi-szteriod aldoszteron antagonistát tartalmazó, szív- és érrendszeri betegségek kezelésére szolgáló kombinált készítmények és alkalmazásuk
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors